Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | HTR1D | P28221 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24938760 | 0.82 | ALOX15 (0.59) | ALOX15SMN1; SMN2MAPTKDM4EHPGD | |
| SCHEMBL7533220 | 0.81 | ALOX15 (0.58) | ALOX15SMN1; SMN2MAPTKDM4EHPGD | |
| SCHEMBL3610243 | 0.81 | MAPT (0.77) | ALOX15SMN1; SMN2MAPTKDM4EHPGD | |
| SCHEMBL30460419 | 0.81 | ALOX15 (0.58) | ALOX15SMN1; SMN2MAPTKDM4EHPGD | |
| SCHEMBL6614852 | 0.81 | ALOX15 (0.58) | ALOX15SMN1; SMN2MAPTKDM4EHPGD | |
| SCHEMBL31426191 | 0.80 | MEN1 (0.47) | ALOX15SMN1; SMN2MAPTTSHRTP53 | |
| SCHEMBL13505450 | 0.78 | MTNR1A (0.53) | MTNR1A | |
| SCHEMBL8886379 | 0.77 | MTNR1A (0.62) | ALOX15SMN1; SMN2MAPTKDM4ETSHR | |
| SCHEMBL25146363 | 0.77 | MAPT (0.59) | ALOX15SMN1; SMN2MAPTKDM4EHPGD | |
| SCHEMBL31622920 | 0.77 | MTNR1A (0.62) | ALOX15SMN1; SMN2MAPTKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026290-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20100003191-A1 | AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS | NAGASAKI UNIVERSITY (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2113258-A1 | AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS | Nagasaki University (JP) | 2009-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003191-A1 | AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS | APP, APBA1, BACE1 | ALOX15 4306/4885SMN1; SMN2 3173/4885MAPT 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.